Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes by David Castel et al.
1 3
Acta Neuropathol (2015) 130:815–827
DOI 10.1007/s00401-015-1478-0
ORIGINAL PAPER
Histone H3F3A and HIST1H3B K27M mutations define two 
subgroups of diffuse intrinsic pontine gliomas with different 
prognosis and phenotypes
David Castel1,2 · Cathy Philippe1 · Raphaël Calmon3 · Ludivine Le Dret1 · 
Nathalène Truffaux1 · Nathalie Boddaert3 · Mélanie Pagès7 · Kathryn R. Taylor4 · 
Patrick Saulnier5 · Ludovic Lacroix5 · Alan Mackay4 · Chris Jones4 · 
Christian Sainte‑Rose6 · Thomas Blauwblomme6 · Felipe Andreiuolo7 · 
Stephanie Puget6 · Jacques Grill1,2 · Pascale Varlet7 · Marie‑Anne Debily1,8 
Received: 24 June 2015 / Revised: 8 September 2015 / Accepted: 10 September 2015 / Published online: 23 September 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
a systematic stereotactic biopsy and were included in 
this observational retrospective study. Histone H3 genes 
mutations were assessed by immunochemistry and direct 
sequencing, whilst global gene expression profiling and 
chromosomal imbalances were determined by microar-
rays. A full description of the MRI findings at diagnosis 
and at relapse was integrated with the molecular profiling 
data and clinical outcome. All DIPG but one were found to 
harbour either a somatic H3-K27M mutation and/or loss of 
H3K27 trimethylation. We also discovered a novel K27M 
mutation in HIST2H3C, and a lysine-to-isoleucine substitu-
tion (K27I) in H3F3A, also creating a loss of trimethyla-
tion. Patients with tumours harbouring a K27M mutation 
in H3.3 (H3F3A) did not respond clinically to radiotherapy 
as well, relapsed significantly earlier and exhibited more 
metastatic recurrences than those in H3.1 (HIST1H3B/C). 
H3.3-K27M-mutated DIPG have a proneural/oligoden-
droglial phenotype and a pro-metastatic gene expression 
Abstract Diffuse intrinsic pontine glioma (DIPG) is the 
most severe paediatric solid tumour, with no significant 
therapeutic progress made in the past 50 years. Recent 
studies suggest that diffuse midline glioma, H3-K27M 
mutant, may comprise more than one biological entity. 
The aim of the study was to determine the clinical and bio-
logical variables that most impact their prognosis. Ninety-
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signature with PDGFRA activation, while H3.1-K27M-
mutated tumours exhibit a mesenchymal/astrocytic phe-
notype and a pro-angiogenic/hypoxic signature supported 
by expression profiling and radiological findings. H3K27 
alterations appear as the founding event in DIPG and the 
mutations in the two main histone H3 variants drive two 
distinct oncogenic programmes with potential specific ther-
apeutic targets.
Introduction
High-grade gliomas are the most common paediatric 
malignant brain neoplasms and among them diffuse intrin-
sic pontine glioma (DIPG) is a leading cause of death from 
solid tumours in children, with no improvement in outcome 
in decades. The median survival below 1 year does not 
properly describe the various outcomes encountered clini-
cally, from rapid growth over a few months to more pro-
longed survival up to 2 years in some cases [58]. Histologi-
cal grading plays no part in diagnosis nor prognostication 
[7]. Surgery is not offered due to the infiltrative nature of 
the neoplasm in a delicate brain structure, and biopsy was 
abandoned in favour of a clinical and radiological diagno-
sis only [1]. Imaging parameters, when limited to morpho-
logical alterations, have not been associated with survival 
either [26].
Paediatric high-grade gliomas (pHGG) were consid-
ered to mimic their adult counterparts until recent genomic 
studies unravelled significant differences between tumours 
arising at different ages [2, 10, 41, 42, 58]. A unique epi-
genetic reprogramming has recently been suggested in 
pHGG by the discovery of recurrent mutations in genes 
encoding histone H3 variants, never described in any other 
type of cancer of any location or age [50, 59]. These hot-
spot mutations were used to define distinct epigenetic and 
biological subgroups of HGG specifically seen in children 
[53]. Supratentorial HGG have recurrent mutations in 
H3F3A encoding histone H3.3, with G34R/V restricted to 
hemispheric tumours, and K27M to those occurring in the 
midline [53]. DIPG exclusively harbours K27M mutations, 
but in histone H3.1 as well as H3.3 genes [8, 20, 56, 59, 
60].
K27M mutations in both genes substitute a key lysine 
residue on the histone H3 tail for a methionine, and have 
been shown to exert biochemical inhibition of the Poly-
comb Repressor Complex 2 (PRC2) resulting in a global 
loss of trimethylation of lysine 27 on all histones H3 mol-
ecules either wild types or mutated [34]. However, a closer 
examination of the epigenome in mutated cells identified 
subtler deregulation with focal gains and maintenance of 
H3K27me3, for which the mechanism remains elusive [3, 
11]. Although differing only by five amino acids, these 
two histone H3 proteins are distinct in terms of expression 
during the cell cycle, chaperones for incorporation in the 
nucleosomes, localisation on the genome and presumably 
physiological functions [23, 54]. Consequently, we sought 
to elucidate if K27M mutations in the distinct histone H3 
variants (i.e. HIST1H3B and H3F3A) were associated with 
a specific biology and performed comprehensive histologi-
cal, radiological, transcriptome and CGH array (aCGH) 
analyses on an extended cohort of DIPG cases biopsied at 
diagnosis selected with stringent clinical, radiological and 
histological integrated criteria.
Materials and methods
Patients and tumour samples
Patients were selected based on classical clinical and radi-
ological criteria, i.e. short clinical history (<3 months of 
symptom duration) and the presence of a pontine tumour 
infiltrating at least 50 % of the pons (suppl. Table S1; suppl. 
Fig S1) [58]. All patients underwent systematic stereotactic 
or surgical biopsy at Necker Hospital (Paris, France). Diag-
nosis of glial infiltrative non-pilocytic neoplasm was histo-
logically confirmed in all patients and we obtained snap-
frozen tumour material from 91 children. A smear of each 
biopsy was performed before freezing and the presence of 
tumour cells was assessed before their use for the genomic 
analyses. Informed consent for the translational research 
programme was obtained from the parents or guardian 
according to the IRB approved protocol (number DC-2009-
955 for tumour banking). Site of the biopsy (routinely the 
junction between the pons and the cerebellar peduncle 
where there was an hypersignal on FLAIR sequences) was 
checked on the post-biopsy imaging [45].
Biopsies from patients with pHGG in a non-brainstem 
location (n = 93) were obtained during the same period at 
Necker hospital. Their histone H3.1/H3.3 mutation status 
was determined by Sanger sequencing.
Sanger sequencing
Histone H3 genes were analysed by direct sequencing of 
PCR-amplified products from tumour DNA using primers 
listed in suppl. Table 2.
Radiological assessment
Morphological sequences of the MRI were reviewed 
independently by three clinicians (neurosurgeon, neuro-
radiologist and oncologist). The following criteria were 
scored on the diagnostic MRI: location, contrast enhance-
ment, ring contrast enhancement, large area of necrosis, 
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cysts, presence of stripes in the infiltrated brain on T2/
FLAIR sequences and tumour size. In case of discrepancy, 
definitive scoring was obtained by consensus. Response to 
radiotherapy was judged by the clinical improvement only 
in patients with stable or decreasing doses of steroids to 
avoid misinterpretation of the radiology due to pseudopro-
gression [12]. Disease extension was registered through-
out the follow-up (i.e. local only, loco-regional or meta-
static). Patients without an MRI in the last 2 months were 
excluded, considering that data were incomplete.
For the diffusion maps acquired at diagnosis, regions of 
interest (ROI) were drawn over the T2 hyperintensity cor-
responding to the tumour in each slice, creating a volume 
of interest (VOI) carefully avoiding necrotic areas, by an 
experienced neuroradiologist blind to the clinical data. 
These VOIs were transferred to the co-registered diffusion 
maps and every voxel value was individually registered. 
Histograms were created from the apparent diffusion coef-
ficient (ADC) and distributed diffusion coefficient (DDC) 
voxel data [32].
The performance in terms of prognostication of the 
recently published “DIPG survival model” was evaluated in 
comparison to other biological stratification. This score is 
based on the assessment of the following parameters: age at 
diagnosis, interval between first symptoms and diagnosis, 
presence of a ring enhancement and use of adjuvant chem-
otherapy in addition to radiotherapy [28].
Histology, immunohistochemistry (IHC) and FISH 
analyses
Tumours were histologically classified according to WHO 
2007 criteria whenever possible. Emphasis was put on the 
presence of an oligodendroglial component in the tumour 
cells (morphology, negativity of the tumour cells for vimen-
tin, positivity for OLIG2), presence of interstitial oedema 
(semi-quantitative) and the presence or absence of necrosis.
A systematic panel of IHC markers was routinely per-
formed: OLIG2, vimentin, GFAP, p53 (DO-7), PTEN, 
EGFR and MIB-1 as previously described [46]. Additional 
stainings were developed to detect the loss of nuclear 
expression of the trimethylation mark at position K27 of the 
histone 3 tail (1:1000, polyclonal rabbit antibody, Diagen-
ode, Belgium), the nuclear expression of the K27M form of 
histone H3 (1:1000, polyclonal rabbit antibody, Millipore, 
CA) and loss of ATRX nuclear expression (1:200, poly-
clonal rabbit antibody, Sigma-Aldrich, MO).
PDGFRA gene copy number was assessed by fluorescent 
in situ hybridization (FISH) using PDGFRA/CEN4 Dual 
Color Probe (Abnova, Tapei, Taiwan) on interphase nuclei. 
In brief, four-micron sections of tumour were mounted on 
SuperFrost Plus slides (Erie Scientific CA., Portsmouth, 
NH) and the probed area determined in accordance with 
haematoxylin and eosin-stained section. The sections were 
deparaffinised in xylene, rehydrated through an ethanol 
series, air-dried and incubated in pre-treatment solution 
(1 M NaSCN-Tris) at 80 °C for 25 min. Slides were then 
treated with a 0.01 % pepsin solution (Sigma-Aldrich, Saint 
Louis, USA) at 37 °C for 8 min. After dehydration, 10 µl of 
probe mixture was applied to each sample, slides were cov-
erslipped and co-denatured at 75 °C for 5 min and hybrid-
ized at 37 °C for 48 h using thermobrite system (Leica Bio-
systems, Richmond, IL). A post-hybridization wash was 
performed in 2 × SSC at 73 °C for 2 min. Preparations were 
dehydrated and counterstained with 4,6-diamidino-phenyl-
indole (DAPI). Signals were scored in at least 100 non-over-
lapping interphase nuclei. PDGFRA gene amplification was 
considered as positive in (A) specimens that have ≥40 % of 
cells displaying ≥4 copies of the PDGFRA signal, (B) spec-
imens that display PDGFRA gene amplification, according 
to one of the following criteria: (a) a PDGFRA to CEN4 
ratio ≥2 over all scored nuclei and calculated using the 
sum of PDGFRA divided by the sum of CEN4 when mean 
CEN4 per cell is ≥2 copies; (b) the presence of gene cluster 
(≥4 spots) in ≥10 % of tumour cells; (c) at least 15 copies 
of the PDGFRA signals in ≥10 % of tumour cells. Results 
were recorded using a DM600 imaging fluorescence micro-
scope (Leica Biosystems, Richmond, IL) and digital imag-
ing software (Cytovision, v7.4).
Genomic and statistical analysis
Gene expression (GE) profiling and comparative genomic 
hybridization on array (aCGH) were conducted for patients 
with enough material available of required quality on an 
Agilent platform. For all statistical analysis, the level of 
significance was 5 %.
Gene expression microarrays analysis
The data analysed is the result of the gathering of DIPG 
samples belonging to three different cohorts of young 
patients with high-grade glioma. In such experimental 
design, a well-known undesired bias is the batch effect, 
which is purely technical. To correct for this effect, we rep-
licated some samples in at least two of three batches and 
performed the ComBat analysis [29] as recommended in 
Chen et al. [13]. A normal brainstem sample from commer-
cial source, hybridized on chips in the three batches, was 
used as a reference to normalize the data for the intensity 
bias as recommended in Do et al. [17]. The normaliza-
tion of fluorescence intensities is performed in two steps, 
inspired by Bolstad et al. [5]. The first one is a loess nor-
malization using the normal brainstem samples as a com-
mon baseline array for all arrays in the cohort. The second 
step is a quantile normalization.
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Differential analysis was then performed using a mod-
erated t test, comparing mean of log2(intensities) in both 
H3.1- and H3.3-mutated DIPG samples, implemented in the 
limma R package. The null hypothesis H0 for each gene is 
that the mean of log2(intensities) is the same in both H3.1- 
and H3.3-mutated DIPG samples. The alternative hypoth-
esis H1 for each gene is that they are different. The obtained 
p values were adjusted for multiple testing using the Benja-
mini–Hochberg procedure. The a priori defined level of sig-
nificance was 5 % after correction for multiple testing.
Comparative genomic hybridization array analysis
Log2(ratio) between raw signals of the reference DNA and 
DIPG DNA was first normalized for the dye and intensity 
effects and also for the local GC % content, using loess 
procedure, implemented in the limma R package [51]. Data 
were then centred according to normalized log2(ratio) dis-
tribution values by an in-house script using the EM (expec-
tation maximization) approach and aberrations status call-
ing was automatically performed. Normalized centralized 
values were then segmented using the Circular Binary 
Segmentation (CBS) algorithm [39], implemented in the 
DNAcopy R package. The normal copy number interval 
[log2(ratio) = 0 which means 2 DNA copies as in the DNA 
reference] was calculated for each sample by multiplying 
with a define factor the median absolute deviation (MAD) 
of the normalized data for each single sample.
Survival curves comparisons
Survival functions were estimated with the Kaplan–Meier 
method and all survival function estimate comparisons 
were performed using a log-rank test. The null hypothesis 
H0 was that the two considered survival function estimates 
were the same. The alternative hypothesis H1 was that they 
were different.
Multivariate survival analysis
The multivariate survival analysis was conducted on H3.1- or 
H3.3-mutated patients only. The other patients (wild type or 
H3.2 mutated) were excluded from this analysis. The pool 
of initial covariates to include in the Cox model was: (1) 
H3-variant mutation, (2) presence of metastasis, (3) MRI 
contrast enhancement, (4) treatment type and (5) DIPG Risk 
score. We first checked for multicollinearity. H3-variant muta-
tion and presence of metastasis are correlated (cor = 0.32) as 
well as MRI contrast enhancement and the DIPG Risk score 
(cor = 0.56). We started the analysis with 4 different pools of 
covariates to separate the correlated pairs of variables and then 
performed a backward stepwise variable selection using the pec 
R package. At the end of the procedure, two models retained 
no variables while the other retained two (‘H3-variant muta-
tion’ and ‘DIPG Risk score’) and three variables (‘H3-variant 
mutation’, ‘treatment type’ and ‘MRI contrast enhancement’), 
respectively. For both models, the coefficient for ‘H3-variant 
mutation’ was 1.4109 and 1.6389, respectively, while the other 
coefficients were much lower (DIPG Risk score coef = 0.0873, 
radiotherapy coef = 0.1101, Tarceva coef = −0.4963, Temodal 
coef = 0.5126, MRI contrast enhancement coef = 0.6573). 
The hazard ratios were 3.98 and 5.00, respectively, and the 
confidence intervals were (0.25; 0.92) and (0.67; 1.93), respec-
tively. The log-likelihood p values were 3.39e−5 and 7.69e−5, 
respectively. The H3-variant mutation is then the most impor-
tant variable in the multivariate Cox model.
Distribution analyses (diffusion data and age 
at diagnosis)
To test if both ADC and DDC values were drawn from the 
same distribution for H3.1- and H3.3-mutated patients, a 
Mann–Whitney test was performed in each case. The null 
hypothesis H0 is that ADC (or DDC, respectively) values 
are drawn from the same distribution law for both H3.1- 
and H3.3-mutated patients. The alternative hypothesis H1 
is that they follow two different distribution laws.
The same methodology was adopted to compare dis-
tributions of age at diagnosis between H3.1- and H3.3-
mutated patients.
Proportions comparisons
To compare sex ratios in H3.1- and H3.3-mutated patients, 
we performed a Chi-squared proportion test as none of the 
theoretical headcounts was below 5. The null hypothesis 
H0 was that the male–female proportions are the same in 
the two considered groups. The alternative hypothesis H1 
was that they are different.
For the response to radiotherapy comparison, there was 
one theoretical headcount below 5, so we performed a 
Fisher exact test instead of the Chi-squared proportion test. 
The null hypothesis H0 was that the proportions of good 
and bad response to radiotherapy were the same in the two 
considered groups.
Results
Loss of H3K27me3 and histone H3 mutation 
as hallmarks of DIPG
We analysed a cohort of 62 DIPG biopsy samples obtained 
at diagnosis for (1) histone H3 lysine 27 trimethyla-
tion (Fig. 1a) and (2) immunodetection of the mutated 
H3-K27M histone (Fig. 1b) by IHC, and correlated 
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these data with the mutational status obtained by Sanger 
sequencing on corresponding biopsy core (Fig. 1c). We 
observed an H3K27me3 loss in 95 % of DIPG samples 
(59/62) (Fig. 1a, c). In the remaining samples, the low 
tumour infiltration of the assayed sample impeded the 
detection of the H3K27me3 loss, but H3-K27M-mutated 
allele could be detected on a distinct sample in two of 
them, indicating that the lack of IHC detection can result 
from heterogeneity of distinct tissue sections (Supplemen-
tal Figure S2a). For the third patient, although showing 
typical DIPG MR Imaging, we did not observe a typical 
histology exhibiting features of a poorly differentiated 
tumour with pseudopalisading necrosis, mitosis and a 
giant cell component (P188, suppl. Fig S2b), an absence 
of OLIG2, but GFAP, S100 and TP53 expression (data 
not shown). Based on the absence of any H3K27me3 
H3-K27M alteration and this particular histology, the 
sample was not considered as a classical DIPG. Of note, 
this tumour was not harbouring any IDH1/2 mutation or 
MYCN amplification.
All but one H3-K27M mutation found by sequencing 
could also be accurately detected by IHC, including a novel 
mutation a gene encoding the H3.2 variant, HIST2H3C, not 
previously described (Fig. 1c, suppl. Fig S2b, c). However, 
a second novel mutation, a lysine-to-isoleucine substitution 
(K27I) in H3F3A resulting from two nucleotide changes 
within the same codon (c.[83A>T; 84G>T]) failed to be 
detected by the H3-K27M staining but presented a loss 
H3K27me3 immunoexpression (suppl. Fig S2b, c). In addi-
tion, we observed qualitative differences in the labelling 
intensity of the H3-K27M in the nuclei of the tumour cells 
between H3.3/H3.2- (strong staining) and H3.1-mutated 
alleles (weak staining, cross-reactivity corresponding to the 
important similarity among the two variants already shown 
[34]) (Fig. 1 a, b, suppl. Fig S2d).
We performed further Sanger sequencing of histones 
HIST1H3B, H3F3A and for wild-type cases. we sub-
sequently examined HIST1H3C and HIST2H3C in an 
extended cohort of 183 pHGG from diverse anatomical 
regions. We identified H3.3-K27M mutations in midline 
tumours whereas H3-G34R/V mutations were restricted 































































Fig. 1  Loss of H3K27me3 as a defining characteristic of DIPG. 
Representative results of IHC for H3K27me3 (a) and H3-K27M (b) 
for a H3.3-K27M-mutated tumour. a An overall strong reduction 
of H3K27me3 is observed with a specific loss of the trimethylation 
mark in the nuclei of the tumour cells (arrows) while the staining is 
preserved in the nuclei of the normal cells (triangles). b H3-K27M-
mutated proteins are detected in the nuclei of the majority of tumour 
cells (brown staining; arrows) with only few normal residual cells 
merely stained in blue (triangles) (scale bar 100 µm). c Plot summa-
rizing the H3K27me3 (left) and H3.3-K27M (right) immunostaining 
on 62 DIPG biopsies together with their respective histone muta-
tion status of lysine 27 of H3.1, H3.2 or H3.3 genes indicated by the 
colour of the ribbons. All but one sample showed either H3K27 tri-
methylation loss or a positive H3.3-K27M immunostaining (61/62; 
98 %). The H3-K27M staining allowed detection of the vast major-
ity (>90 %, 56/62) of H3.1- and H3.3-K27M-mutated tumours, and 
also the rare H3.2-K27M variant. It failed to detect the other rare 
H3.3-K27I-mutated sample. Overall, 59/62 specimens analysed 
showed a loss of the trimethylation mark including some histone 
wild-type (WT) samples (6). d Anatomical distribution of histone 
H3 mutations in 183 pHGG. WT tumours are found throughout the 
brain (grey) whereas H3.3-K27M mutants (dlight green) are found in 
midline pHGG and H3.3-G34R/V (blue) are restricted to the cortex. 
H3.1-K27M substitutions appeared specific to DIPG tumours and the 
unique H3.3-K27I and H3.2-K27M found in our cohort also corre-
spond to DIPG
▸
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H3.2-K27M, as well as H3.3 K27I, were only found in 
pontine tumours (Fig. 1d).
Landscape of genomic alterations in H3.3‑ 
and H3.1‑mutated DIPG
Given the discrepancies in H3.1 and H3.3 functions and 
genomic localization, we next explored the differences 
between H3.3- and H3.1-mutated tumours using integrated 
DNA copy number and gene expression analysis.
We identified a signature of 23 and 160 differentially 
expressed genes (DEGs) using adjusted p value cutoff 
of 1 and 5 %, respectively (Fig. 2, suppl. Fig S3a; suppl. 
Table 3) which allowed a fair discrimination of the 2 sub-
groups. Among the 23 most DEGs were four homeobox 
genes HOXD8, IRX4, TLX2 and PRRX1, as well as three 
direct TP53 effectors (DDB2, FDXR and PMAIP1) overex-
pressed in H3.1- vs. H3.3-mutated tumours.
We further conducted genome-wide aCGH analy-
sis to determine the subgroup specificity of DNA copy 
number alterations. We observed a more frequent gain 
of chromosomes 1q (83 vs. 44 %; p value = 0.035) and 
2 (75 vs. 16 %; p value = 0.0008) in the H3.1 subgroup, 
whereas loss of 17p13.1 (8 vs. 48 %; p value = 0.0272) 
was preferentially found in H3.3 tumours (Fig. 2). These 
data were significantly correlated with gene expression 
modulations of the genes located in these regions (data not 
shown). As the latter locus corresponds to TP53, previ-
ously shown mutated at least in 40 % of DIPG [8, 20, 24, 
60], we evaluated expression by IHC and found exclusive 
p53 accumulation in H3.3-K27M samples (Fig. 2, S3b; p 
value = 0.0001). Gene set enrichment analysis (GSEA) of 
our expression profiling data accordingly showed down-
regulation of TP53 targets (suppl. Fig S3b). Likewise, gain 
or amplification of PDGFRA locus (4q12) was only seen 
in H3.3 tumours and the overexpression of genes upregu-
lated in PDGFRA-amplified pHGG [41] was only observed 
in the H3.3-K27M subgroup (suppl. Fig S3c, d). ATRX 
expression was also evaluated by IHC, and ATRX loss was 
only found in 24 % of H3.3-mutated tumours (suppl. Fig 
S3e, f). Finally, ACVR1 mutations were exclusively found 
in H3.1-K27M tumours (Fig. 2, suppl. Fig S3g) as previ-
ously described [8, 20, 56, 60].
K27M mutations in H3.3 and H3.1 mutations drive two 
distinct oncogenic programmes
In-depth analysis of GE profiling of the two subtypes 
showed a strong enrichment for the proneural-glioblastoma 
multiforme (GBM) [57], oligodendrocytic [9] or neural [21] 
signatures in H3.3-K27M tumours (Figs. 3a, S4a). With 
respect to histology, an oligodendroglial differentiation was 
observed more frequently in H3.3-K27M DIPG (Fig. 3a, p 
value = 0.0019). Moreover, we found a significant down-
regulation of genes inhibited in metastases [4, 14, 22, 38, 44, 
47, 55] (Fig. 3b, suppl. Fig S4b–g). This observation is fully 
concordant with our clinico-radiological follow-up of 41 
DIPG patients who had an MRI within the last 2 months of 
life, which indicated that all but one of fifteen patients pre-
senting a metastatic relapse belonged to the H3F3A-mutated 
subgroup (p value = 0.04). Ten of them had symptoms 
before death related to the metastases (seizures, raised intrac-
ranial pressure without hydrocephalus) (Fig. 3c, suppl. Fig 
S4 h–p). Related to this, GSEA analysis revealed a depletion 
for GO categories related to ECM receptor interaction and 
cell–matrix adhesion—confirming an alteration of adhesion 
properties in H3.3 tumours (Fig. 3d, e), and also deregulation 
in gated channel activity-related genes which can modify 
migration and invasion properties [16, 25] (suppl. Fig S4q).
In H3.1-mutated tumours, we identified the overex-
pression of genes linked to the mesenchymal glioblas-
toma subtype [21, 57] and astroglial cells [9] (Figs. 4a, 
S5a). These samples also showed an upregulation of 
genes involved in angiogenesis and a hypoxia signature 
with a predicted underlying HIF1A activation (Figs. 4b, 
c, S5b, c). These molecular characteristics were both 
corroborated by T1-contrast enhancement MRI data, 
showing the presence of large necrotic areas in the H3.1-
K27M tumours (Figs. 4b, S6). In addition, extracellular 
oedema appeared as a hallmark of the H3.1 subgroup. 
First, expression microarray analysis showed a sig-
nificant enrichment of genes upregulated in GBM with 
oedema (High Flair; Fig. 4d). In addition, histologi-
cal analysis of our extended cohort of 57 DIPG showed 
more extensive extracellular oedema in H3.1 than H3.3 
tumours with the presence of extracellular vacuoles 
(Fig. 4d,e, p value 0.0017). Finally in the diffusion-
weighted MR imaging, H3.1- and H3.3-mutated tumours 
exhibited different distribution of the ADC and more 
strikingly DDC values, pointing to differential water dis-
tribution (Fig. 4f).
HIST1H3B K27M mutation is associated with a less 
aggressive behaviour in DIPG
Given the aforementioned differences in H3.1- and H3.3-
K27M tumours, we next compared their clinical character-
istics. We did not find any significant difference in terms 
of sex ratio (Fig. 5a), but found an earlier onset of the dis-
ease for H3.1 patients of approximately 2 years (Fig. 5b; 
p value <0.0001, Mann–Whitney test) in our cohort and 
in a previously published one [8, 20, 60] (suppl. Fig S7a, 
b). More importantly, H3.1 patients were associated with 
a better clinical response to radiotherapy (85 vs. 55.3 % 
of good clinical responders, p value = 0.0263), and over-
all survival length (OS), with a median OS of 15.0 months 























































































































































































Fig. 2  Landscape of genomic alterations in H3.3- and H3.1-mutated 
tumours. Unsupervised hierarchical clustering and heatmap asso-
ciated with the gene expression profile of the 23 DEGs (Benjamini 
and Hochberg adjusted p value <0.01) between H3.1- and H3.3-
mutated subgroups. The main recurrent genomic alterations found 
by aCGH, the mutational status of histone H3F3A (light green), 
HIST1H3B (dark green) and ACVR1 (purple) as well as TP53 pro-
tein accumulation evaluated by IHC of the 39 primary tumour speci-
mens analysed are reported above the heatmap. TP53 protein accu-
mulation was found exclusively in H3.3 subgroup as well as most 
genomic imbalances of the corresponding genomic region 17p13.1. 
Loss of the cytoband 14q24 appears also more often in H3.3 samples 
whereas H3.1 tumours are characterized by a frequent gain of chro-
mosome 1q and had significantly more aberrations of chromosome 2 
(p value = 0.0062, Fisher exact test). Gene expression levels in com-
parison with normal brainstem are illustrated by varying shades of 
orange (upregulation) and blue (downregulation)
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for patients with H3.1 mutations compared to 9.2 months 
for H3.3-mutated patients (Fig. 5c, d; p value = 4.51e−05, 
log-rank test). Re-analysis of published cases confirmed 
the overall better prognosis of H3.1-K27M tumours in 
an independent cohort [60] (suppl. Fig S7c). Finally, we 
tested in our cohort other previously published prognostic 
classifications based on ACVR1 mutation (suppl. Fig S7d, 
e), Histone H3 WT/K27M status [31] (suppl. Fig S7f), or 
stratification according to metastatic evolution or treatment 
administered (suppl. Fig S7g, h), clinico-radiological risk 
score [28] (suppl. Fig S7i), MRI contrast enhancement [43] 
(suppl. Fig S7j). None of these risk factors was a stronger 
predictor for survival than the type of mutated histone H3 
which remained as such in multivariate analysis (p value 
<0.0001).
Discussion
Mutations in the N-terminal tail of histone H3 genes have 
been recently found in midline pHGG and at particular high 
frequency in DIPG. Our results support that substitution 
of the lysine at position 27 of genes encoding H3, which 
can be detected by IHC through its consequences, i.e. the 
global loss of trimethylation on this residue, is the driving 
event in DIPG oncogenesis. In addition to K27M mutations 
in genes encoding H3.3 (H3F3A) and H3.1 (HIST1H3B 
and HIST1H3C) found in the majority of samples as previ-
ously reported, we also identified two novel lysine 27 sub-
stitutions. The first was a novel K27M mutation in a gene 
encoding histone H3.2 (HIST2H3C) implying that which-
ever histone H3 variant is targeted by the mutation (H3.1, 
H3.2 or H3.3), it may lead to the development of a DIPG. A 
further argument for the importance of alterations of these 
residues is the discovery of a second novel mutation, two 
base changes being required to produce a K27I lysine-to-
isoleucine substitution in H3.3 (H3F3A). Although reported 
here in a DIPG sample for the first time, systematic in vitro 
modification of the lysine 27 predicted K27I as the only 
substitution other than K27M to result in a repressive effect 
on H3K27me3 [34]. In summary, our data underline the 
pivotal importance in this disease of H3K27 mutations and 
loss of H3K27me3, which is consequently characteristic of 
DIPG and likely represents the first genomic event leading 
to transformation in these tumours. DIPG thus appears as 
a homogeneous tumour group defined as a glial neoplasm 
with a stereotypical epigenetic drive consecutive to these 
histone H3 mutations.
All H3K27 mutations described in DIPG appear to have 
the same epigenomic consequences on the PRC2 com-
plex in general [11, 34] despite the distinct functions and 


















































































































































Fig. 3  Integrated molecular and phenotypic portrait of H3.3 mutant 
DIPG. a Oligodendrocytic and proneural gene expression signatures. 
Gene Set Enrichment Analysis (GSEA) was conducted to identify 
gene sets that exhibited significant overlaps with gene overexpressed 
in the H3.1-mutated subgroup. The rank order of genes from the 
most upregulated (left, position 1) to the most downregulated (right, 
position 15,198) in H3.1 vs. H3.3 is shown in x-axis and the barcode 
illustrates the position of genes belonging to a particular gene set. 
The running enrichment score, generated by the cumulative tally of 
the gene set plotted as a function of the position within the ranked list 
of array probes, is shown as a green line. The total height of the curve 
indicates the extent of enrichment, with corresponding normalized 
enrichment score (NES) and false discovery rates (FDR) indicated. 
Upregulated genes in oligodendrocytes [9] and genes correlated with 
proneural type of GBM tumours [57] are enriched in H3.3 samples. 
Accordingly, histology and IHC showed a strong enrichment of 
tumour with an oligodendrocytic phenotype in H3.3-mutated samples 
(right panel, p value = 0.0019; Fisher exact test). b Preferential met-
astatic progression. GSEA analysis shows that the top genes inhibited 
in metastatic vs. non-metastatic bladder cancer cell lines [22] were 
also downregulated in H3.3 vs. H3.1 subgroups. c Complete clini-
cal follow-up of 41 DIPG patients who had an MRI within the last 
2 months of life shows that metastatic evolution was mostly observed 
in patients with H3.3-K27M mutation (p value = 0.04; two-sided 
Fisher exact test). d, e Enrichment of genes associated with ‘extracel-
lular matrix receptor interaction’ (KEGG pathway) and ‘cell–matrix 
adhesion pathways’ (GO:0007160) in H3.3 vs. H3.1 mutant DIPGs
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it is clear that the type of histone targeted by K27 altera-
tions greatly influences the survival length of patients. 
H3.1-mutated tumours were found to respond better to 
the treatment, mainly radiotherapy, have a less aggressive 
course and metastasize less frequently. As the significant 
effect on OS length was confirmed by the re-analysis of an 
independent series [60], assessment of the type of histone 
mutation could be used as a prognostic stratification fac-
tor in future prospective studies. Moreover, in multivariate 
analysis considering also the effect of treatment, the type 
of histone H3 mutated was a better predictor for survival 
length than the DIPG clinico-radiological risk score [28] or 
the presence of an ACVR1 mutation identified in a subset 
of DIPG with a less aggressive course [56, 60]. The latter 






























































































































































































Fig. 4  Integrated molecular and phenotypic portrait of H3.1 mutant 
DIPG. a Statistical significant enrichment of mesenchymal-like glio-
blastoma multiforme (GBM) [57] and astroglia [9] signatures was 
found in H3.1 tumours by GSEA analyses. Normalized enrichment 
score (NES) and false discovery rates (FDR) values are indicated. b 
A substantial overrepresentation of genes involved in angiogenesis 
pathway (biological process GO: 0001525) was identified in H3.1-
mutated tumours (left panel). This was further confirmed by MRI 
data (right panel) displaying the percentage of samples within H3.1 
or H3.3 subgroups associated with distinct contrast enhancement pat-
terns as described in suppl. Fig S6. The distribution of samples within 
the four classes of patterns is significantly different between H3.1 
(n = 23) and H3.3 (n = 49) subgroups (p value = 0.0234, Chi-square 
test) with a larger proportion of H3.1 samples presenting a large 
necrotic area. (CE contrast enhancement). c Accordingly, hypoxic 
characteristics of H3.1 tumours was revealed by a significant enrich-
ment of the set of genes upregulated by hypoxia in both astrocytes 
and HeLa cells (left panel) [37]. An ingenuity pathway analysis iden-
tified HIF1A as a key upstream regulator (activation z score = 2.177; 
p value = 7.67e−07) that connects a set of overexpressed genes (red 
nodes) in H3.1 vs. H3.3 samples identified by microarray analysis 
(right panel: orange edge leads to activation, yellow edge inconsist-
ent state, grey edge effect not predicted). d Oedema is associated 
with H3.1 tumours. GSEA analysis shows a significant enrichment of 
genes upregulated in GBM with oedema (as defined by high FLAIR 
MRI) for H3.1 vs. H3.3 tumours [61] (left panel). Histological analy-
sis of 57 DIPG showed more extensive extracellular oedema in H3.1 
than H3.3 tumours (right panel; p value = 0.0017, Chi-square test). 
e Representative pictures of the histological examination of extracel-
lular oedema in H3.3 (left panel sample P044)- and in H3.1-mutated 
tumour (right panel sample P070). Oedema appears at the histologi-
cal level in H3.1 sample as multiple interstitial clear vacuoles in H&E 
staining (scale bar 50 µm). f Voxel-based analyses of apparent dif-
fusion coefficient (ADC, top panel) and distributed diffusion coeffi-
cient (DCC, bottom panel) in 10 H3.1- and 10 H3.3-mutated DIPG. 
x-axis represents the ADC or DDC values in µm2/s while the y-axis 
represents the number of pixels with the corresponding value normal-
ized by the total number of pixels analysed (density). ADC and DDC 
values are overall lower and the spread of the distribution smaller in 
H3.1 tumours compared to H3.3 ones. Median ADC values are 1228 
and 1612 µm2/s in H3.1 and H3.3, respectively (p < 0.001, Mann–
Whitney test) whereas normal brain values are 1000 µm2/s. Median 
DDC values are of 2688 and 1499 µm2/s (p < 0.001, Mann–Whitney 
test) in H3.3 tumours compared to H3.1 tumours)
▸
824 Acta Neuropathol (2015) 130:815–827
1 3
the segregation of this alteration with H3.1-K27M mutation 
rather than the reverse. Indeed, no difference was observed 
among the H3.1 tumour subgroup between ACVR1 WT- 
and ACVR1-mutated samples (Fig S7e). Also, the high fre-
quency of metastatic progression in H3F3-mutated DIPG, 
if confirmed in an independent series, could suggest a dif-
ferent therapeutic approach in the subset of patients with 
tumours prone to dissemination.
Our GE profiling data suggest that the two main histone 
H3 mutations drive distinct oncogenic programmes, an 
observation further strengthened by the integration of histo-
logical and MR-imaging data. Notably, the less aggressive 
H3.1 tumours appeared to be more hypoxic and oedema-
tous, as well as exhibiting higher expression of neo-angio-
genic markers than their H3.3 counterpart. A bias towards 
oligodendroglial and astroglial differentiation was observed 
for H3.3 and H3.1 tumours, respectively. Also, the dra-
matic metastatic evolution of the disease—observed almost 
exclusively in H3.3-K27M samples, could be partially 
explained by the identification of deregulated genes encod-
ing ion-gated channels and adhesion molecules known to 
play a role in this invasion process [15, 52]. Despite their 
different progression rate, we did not find discrepancies in 
MIB-1 proliferative index between the two groups.
We show here that the H3-K27M-mutated DIPG group 
recognized by previous studies [7, 8, 31] could be further 
divided into two subgroups, H3.1-K27M and H3.3-K27M. 
There is significant overlap between the H3.3-K27M sub-
group and the PDGFRA-driven DIPG shown previously 
and between the H3.1-K27M subgroup and the tumours 
with a mesenchymal gene expression signature [40, 46]. 
The wild-type DIPG (with respect to histone H3 muta-
tion) described by other groups [8, 31], is also found 
in our series, but we did not find differences in survival 
between WT and H3-K27-mutated groups in this popula-














































































Fig. 5  Histone H3 mutations define two clinical DIPG subgroups. a 
Sex distributions of cases with H3.1 or H3.3 mutations show a trend 
towards an increased proportion of females in H3.1 mutant samples 
(56.5 vs. 46.4 %) which did not reach statistical significance. b Age 
distribution of H3.1 and H3.3 patients at diagnosis. The median age 
at diagnosis was significantly smaller in H3.1 (5.1 years) in com-
parison with H3.3 (7.4 years). Statistical significance was calculated 
with Mann–Whitney test (median, ****p value <0.0001, n = 79). c 
Bar diagrams representing the response to radiation therapy strati-
fied by H3.1 and H3.3 mutation status. The vast majority of H3.1-
mutated patients (85 %) were identified as good responders to radia-
tion therapy whereas H3.3-mutated cases are divided evenly between 
the responders and non-responders group (55.3 %, p value = 0.0263, 
two-sided fisher exact test). d Kaplan–Meier estimates of the survival 
stratified by H3.1- or H3.3-K27M mutations. H3.1 tumours are asso-
ciated with a better overall survival than H3.3 tumours (median sur-
vival times of 15.0 and 9.2 months, respectively, p value = 4.51e−05; 
log-rank test)
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all but one of the silent tumours we describe had a loss of 
the trimethylation mark at K27 of the histone H3. As this 
is an indication of the functional impairment of the PRC2 
complex, alternative mechanisms have to be explored to 
confirm these tumours could be grouped together with the 
histone H3-27 M-mutated ones. We did not find a MYCN 
amplification, nor an IDH1/2 mutation in the only sample 
without trimethylation loss at K27 of the histone H3 (case 
P188; suppl. Fig S2). MYCN-amplified cases may corre-
spond to a PNET-like variant and are in fact relatively rare 
(less than ten cases reported so far in the whole literature 
with MYCN amplification).
The differences between the H3.3/H3.1 subgroups may 
be a result of distinct cells of origin for these tumours, or 
reflect a mechanistic consequence of the type of histone 
mutated. Interestingly, we identified a differential expres-
sion between these subgroups of numerous homeobox 
genes, known to be pivotal for neural stem cell identity and 
tissue patterning. This coupled with the earlier age of onset 
of the H3.1-mutated tumours as well as their restricted pon-
tine location (as opposed to H3.3 mutations also found in 
HGG of other midline regions) could imply that distinct 
progenitors are targeted by the two mutations. Equally, 
homeobox clusters are known to be regulated by the PRC2 
complex [49] and the epigenetic consequences of the PRC2 
complex inhibition might have regional differences depend-
ing on the histone type. Secondary genetic alterations also 
co-segregate between the two subgroups. PDGFRA ampli-
fication/mutation, a known inducer of oligodendrocytic dif-
ferentiation [6, 19, 48], is seen together only with histone 
H3.3 mutations, whilst ACVR1 mutations that activate the 
BMP pathway driving astrogenesis are only concomitantly 
observed with mutant H3.1. Still, the gene expression sig-
nature between H3.1 and H3.3 subgroups may not be due 
to the H3 mutations themselves but rather the accompany-
ing alterations (PDGFRA vs. ACVR1) or differential modi-
fication of the microenvironment by tumour cells. However, 
the astrocytic phenotype was observed in the H3.1-mutated 
tumours independently of the ACVR1 mutation and future 
work in vitro should help unravel this matter.
In conclusion, biopsies performed at diagnosis allowed 
us to confirm a DIPG in almost every case by the identifica-
tion of a specific histone H3K27 alteration. The type of his-
tone H3 mutated could also predict the outcome of DIPG 
patients more efficiently than clinical and radiological 
characteristics of the tumours. Moreover, two distinct onco-
genic pathways associated with the mutated histone-driven 
subgroups have been identified in DIPG and different thera-
peutic approaches may be developed to target these specific 
alterations and phenotypic changes. Conversely, mutually 
exclusive alterations observed in the two DIPG subgroups 
may influence the response to a given targeted agent. Cru-
cially, our results justify the re-introduction of stereotactic 
biopsies at diagnosis in the management of DIPG for better 
treatment stratification decisions.
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